Victory Capital Management
DYN icon

Victory Capital Management’s Dyne Therapeutics DYN Stock Holding History

Victory Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21M Buy
54,498
+1,518
+3% +$28.2K ﹤0.01% 1823
2026
Q1 		$961K Buy
52,980
+1,496
+3% +$25.8K ﹤0.01% 1859
2025
Q4 		$1.01M Buy
51,484
+1,382
+3% +$26.2K ﹤0.01% 1831
2025
Q3 		$634K Sell
50,102
-16,311
-25% -$186K ﹤0.01% 1997
2025
Q2 		$632K Buy
66,413
+7,002
+12% +$77.1K ﹤0.01% 2009
2025
Q1 		$621K Sell
59,411
-1,937
-3% -$27.7K ﹤0.01% 1973
2024
Q4 		$1.45M Buy
61,348
+30,811
+101% +$911K ﹤0.01% 1629
2024
Q3 		$1.1M Buy
30,537
+11,385
+59% +$453K ﹤0.01% 1742
2024
Q2 		$676K Buy
+19,152
New +$557K ﹤0.01% 1882

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Victory Capital Management's DYN Position: Q2 2026 in Review

Victory Capital Management increased its Dyne Therapeutics (DYN) stake by 2.9% in Q2 2026, buying an estimated $28.2K and bringing the position to 54,498 shares worth $1.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1823.

Victory Capital Management first reported a position in DYN in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.45M in Q4 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Victory Capital Management held 54,498 shares of Dyne Therapeutics worth $1.21M as of Q2 2026.
  • Victory Capital Management bought 1,518 Dyne Therapeutics shares in Q2 2026, an estimated $28.2K.
  • Dyne Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1823 holding.
  • Victory Capital Management first reported a position in Dyne Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Victory Capital Management's Dyne Therapeutics position peaked at $1.45M in Q4 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.